Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Change in Account Payables (2016 - 2021)

Historic Change in Account Payables for Guided Therapeutics (GTHP) over the last 11 years, with Q2 2021 value amounting to -$84000.0.

  • Guided Therapeutics' Change in Account Payables fell 19767.44% to -$84000.0 in Q2 2021 from the same period last year, while for Jun 2021 it was -$446000.0, marking a year-over-year decrease of 456000.0%. This contributed to the annual value of -$372000.0 for FY2020, which is 196000.0% down from last year.
  • Per Guided Therapeutics' latest filing, its Change in Account Payables stood at -$84000.0 for Q2 2021, which was down 19767.44% from $29000.0 recorded in Q1 2021.
  • In the past 5 years, Guided Therapeutics' Change in Account Payables registered a high of $148000.0 during Q1 2017, and its lowest value of -$208000.0 during Q3 2020.
  • In the last 5 years, Guided Therapeutics' Change in Account Payables had a median value of $20500.0 in 2018 and averaged $388.89.
  • Its Change in Account Payables has fluctuated over the past 5 years, first skyrocketed by 35333.33% in 2019, then plummeted by 73030.3% in 2020.
  • Guided Therapeutics' Change in Account Payables (Quarter) stood at $54000.0 in 2017, then decreased by 22.22% to $42000.0 in 2018, then tumbled by 200.0% to -$42000.0 in 2019, then plummeted by 335.71% to -$183000.0 in 2020, then surged by 54.1% to -$84000.0 in 2021.
  • Its Change in Account Payables was -$84000.0 in Q2 2021, compared to $29000.0 in Q1 2021 and -$183000.0 in Q4 2020.